JP2016515524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515524A5 JP2016515524A5 JP2016503174A JP2016503174A JP2016515524A5 JP 2016515524 A5 JP2016515524 A5 JP 2016515524A5 JP 2016503174 A JP2016503174 A JP 2016503174A JP 2016503174 A JP2016503174 A JP 2016503174A JP 2016515524 A5 JP2016515524 A5 JP 2016515524A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 102220134332 rs142032681 Human genes 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102220623376 Non-histone chromosomal protein HMG-14_T54Y_mutation Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102200016465 rs104894275 Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102220594689 Neurogenic differentiation factor 6_S29K_mutation Human genes 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 102220469723 Voltage-dependent L-type calcium channel subunit beta-2_S53K_mutation Human genes 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102220320593 rs1554306309 Human genes 0.000 claims 2
- 102220092171 rs770694213 Human genes 0.000 claims 2
- 102220125344 rs886043940 Human genes 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798235P | 2013-03-15 | 2013-03-15 | |
| US61/798,235 | 2013-03-15 | ||
| PCT/US2014/029634 WO2014145000A2 (en) | 2013-03-15 | 2014-03-14 | Anti-cd25 antibodies and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515524A JP2016515524A (ja) | 2016-05-30 |
| JP2016515524A5 true JP2016515524A5 (enExample) | 2017-04-13 |
Family
ID=50897881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503174A Pending JP2016515524A (ja) | 2013-03-15 | 2014-03-14 | 抗ｃｄ２５抗体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20150010539A1 (enExample) |
| EP (2) | EP3216804A3 (enExample) |
| JP (1) | JP2016515524A (enExample) |
| CN (1) | CN105377892A (enExample) |
| AU (1) | AU2014233478A1 (enExample) |
| BR (1) | BR112015023084A2 (enExample) |
| CA (1) | CA2904532A1 (enExample) |
| HK (1) | HK1220470A1 (enExample) |
| MX (1) | MX2015012551A (enExample) |
| RU (1) | RU2015144026A (enExample) |
| WO (1) | WO2014145000A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CN110546162B (zh) | 2017-03-28 | 2021-09-07 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| TW201940515A (zh) | 2018-03-13 | 2019-10-16 | 英商塔斯克療法有限公司 | 抗-cd25抗體藥劑 |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP4151655A1 (en) * | 2020-05-14 | 2023-03-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| JP7773172B2 (ja) * | 2021-06-11 | 2025-11-19 | 国立大学法人 新潟大学 | Ｔ細胞増殖促進ペプチド |
| EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| JP2024532790A (ja) * | 2021-08-09 | 2024-09-10 | 南京▲諾▼艾新生物技▲術▼有限公司 | 組換え抗ヒトｃｄ２５抗体及びその使用 |
| CN118355031A (zh) | 2021-09-03 | 2024-07-16 | Go医疗股份有限公司 | 抗糖-lamp1抗体及其用途 |
| AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN120981564A (zh) | 2023-03-17 | 2025-11-18 | 圭尔医疗有限公司 | 调节性t细胞疗法 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| KR100663319B1 (ko) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| RU2337107C2 (ru) * | 2003-05-02 | 2008-10-27 | Ксенкор, Инк. | ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| CN103394083B (zh) | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CN104447992A (zh) * | 2004-09-23 | 2015-03-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| CN101544695B (zh) * | 2008-03-27 | 2012-01-11 | 四川大学华西医院 | 人源化抗cd25单链抗体及制备方法 |
| US8314213B2 (en) * | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| WO2010126890A1 (en) * | 2009-04-27 | 2010-11-04 | Facet Biotech Corporation | Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
| WO2011120134A1 (en) * | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| AU2011279044B2 (en) * | 2010-07-15 | 2013-12-19 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods |
| CN103374074A (zh) * | 2012-04-28 | 2013-10-30 | 中国科学院上海生命科学研究院 | 一种抗cd25单链抗体 |
-
2014
- 2014-03-14 WO PCT/US2014/029634 patent/WO2014145000A2/en not_active Ceased
- 2014-03-14 EP EP17157958.4A patent/EP3216804A3/en not_active Withdrawn
- 2014-03-14 HK HK16108469.7A patent/HK1220470A1/zh unknown
- 2014-03-14 JP JP2016503174A patent/JP2016515524A/ja active Pending
- 2014-03-14 BR BR112015023084A patent/BR112015023084A2/pt active Search and Examination
- 2014-03-14 EP EP14729110.8A patent/EP2970488A2/en not_active Withdrawn
- 2014-03-14 MX MX2015012551A patent/MX2015012551A/es unknown
- 2014-03-14 CN CN201480021398.5A patent/CN105377892A/zh active Pending
- 2014-03-14 RU RU2015144026A patent/RU2015144026A/ru not_active Application Discontinuation
- 2014-03-14 AU AU2014233478A patent/AU2014233478A1/en not_active Abandoned
- 2014-03-14 CA CA2904532A patent/CA2904532A1/en not_active Abandoned
- 2014-03-14 US US14/214,089 patent/US20150010539A1/en not_active Abandoned
-
2017
- 2017-05-03 US US15/585,404 patent/US20170233481A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/899,399 patent/US20200308290A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515524A5 (enExample) | ||
| RU2015144026A (ru) | Антитела против cd25 и их применения | |
| RU2015144033A (ru) | Антитела против cd25 и их применения | |
| JP2012254092A5 (enExample) | ||
| JP2010227116A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| EA201391789A1 (ru) | TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| JP2019523753A5 (enExample) | ||
| PH12016500859B1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| JP2016514691A5 (enExample) | ||
| JP2019527047A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2018085988A5 (enExample) | ||
| JP2015143226A5 (enExample) | ||
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2019523221A5 (enExample) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2016521688A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2017522888A5 (enExample) |